In this task, you're given a passage that represents a legal contract or clause between multiple parties. Your job is to write questions that ask the basic details corresponding to the legal contracts or clauses. Avoid questions that can be answered correctly without actually understanding the paragraph, and which might have multiple answers. The answer to each question should be unambiguous.

[EX Q]: EXHIBIT 10.27

                                                          MediaLinx File No. 952

                         CO-BRANDING CONTENT AGREEMENT                          -----------------------------

THIS AGREEMENT made as of the 30th day of June 1999

BETWEEN:

          MEDIALINX INTERACTIVE, L.P.,           represented herein by its general partner           MediaLinx Interactive Inc.           a corporation incorporated under the laws           of the Province of Ontario           20 Richmond Street East           Suite 600           Toronto, Ontario           M5C 3B5

          (hereinafter called MLX, or Party)

               - and -

          HEALTHCENTRAL.COM INC.           a corporation incorporated under the           laws of the state of California           Marketplace Tower           6001 Shellmound Street, Suite 800           Emeryville, CA. 94608

          (hereinafter called HCI or Party)

          (both MLX and HCI to be collectively referred to as the Parties)

WHEREAS MLX owns, hosts, licenses, publishes and maintains an Internet service in Canada that includes, but is not limited to the Sympatico web site which includes inter alia, the HealthyWay web site on the World Wide Web (the MLX Internet Services);

AND WHEREAS HCI owns, hosts, licenses, publishes and maintains a health services web site known as healthcentral.com on the World Wide Web (the HCI Site);

NOW THEREFORE in consideration of the mutual covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

CERTAIN INFORMATION ON THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

1.  SERVICES & DEVELOPMENT

a)   MLX and HCI have agreed to provide certain services and content to each      other in order to mutually develop and integrate content from the HCI Site      into the Sympatico health section, currently known as HealthyWay, of the      Sympatico web site (the Co-Branded Site).

b)   The Parties have agreed that they will mutually approve the design of the      Co-Branded Site and that the launch date of the Co-Branded Site shall be      September 1st, 1999 unless mutually extended by the Parties as agreed to in      writing.

2.  MLX'S OBLIGATIONS AND RESPONSIBILITIES

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





During the Term of this Agreement MLX shall:

a)   continue to technically host and moderate all of the HealthyWay discussion      forums currently residing on the forums section of the Sympatico web site.      MediaLinx shall retain all right, title to and interest in the discussion      forums;

b)   promote the Co-Branded Site as set out in Schedule 1 attached hereto;

c)   grant to HCI, a non-exclusive and non-transferable right to use MediaLinx      images and certain content contained in the HealthyWay web site (the      Sympatico Content) for the sole purpose of satisfying the requirements of      this Agreement. MediaLinx shall retain all right, title to and interest in      the Sympatico Content;

d)   grant to HCI, to the extent that HCI requires access to MLX logos and      trademarks (collectively MLX Marks) the use of certain MLX Marks as      necessary for the purposes of fulfilling its obligations under this      Agreement. HCI assures that the MLX marks are used in accordance with MLX's      logo usage guidelines as provided by MLX from time to time. Without      limiting the generality of the foregoing, HCI agrees:

     (i)     that MLX is the owner of the MLX Marks and the goodwill and              reputation associated therewith;

     (ii)    not to contest the validity of the MLX Marks or MLX's title              thereto;

     (iii)   that HCI acquires no right, title or interest in the MLX Marks, and              any and all goodwill associated with the MLX Marks enures              exclusively to the benefit of MLX;

     (iv)    to notify MLX promptly of any attempt by any third party to use MLX              Marks, or any variation or imitation thereof of which HCI becomes              aware;

     (v)     at MLX's expense, to fully co-operate with MLX and execute such              documents and at the request of MLX to do such acts and things as              may be reasonably necessary or desirable to restrain such use;

e)   ensure that in the event that it enters into an electronic commerce      agreement with a third party for the sale of goods on the Co-Branded Site      that all agreements with the third parties shall ensure that such third      party shall be wholly responsible for all products and transactions that      may occur on the Co-Branded Site, that all such transactions shall comply      with all applicable Canadian and US laws and regulations, including privacy      laws and including compliance with MediaLinx's standards and guidelines,      and ensure that such third party

                                                                               2

     provides a full indemnity to MediaLinx and HCI in respect of any and all      transactions and products that may be hosted on the Co-Branded Site;

f)   ensure that in the event that user traffic to the Co-Branded Site falls      below the levels outlined in Schedule 2, that MediaLinx will use all      commercially reasonable efforts to increase promotion to the Co-Branded      Site until usage to the site increases to levels above the levels outlined      in Schedule 2; and

g)   make a reasonable effort to explore the technical possibilities of sharing      with HCI the traffic on the home page of the Sympatico Health Section of      the Sympatico web site, subject to any legal and regulatory constraints.

3.  HCI's OBLIGATIONS AND RESPONSIBILITIES

During the Term of this Agreement HCI shall:

a)   use reasonable commercial efforts to provide industry accepted standards of      reliability of service and to make available the appropriate production      resources to build and maintain the Co-Branded Site;

b)   integrate content contained in the HCI Site into the Co-Branded Site of the

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





     Sympatico web site subject to the prior approval of MediaLinx;

c)   update the look and feel of the Co-Branded Site upon Launch, subject to      the prior approval and consent of MediaLinx;

d)   ensure that general terms and conditions on the Co-Branded Site are subject      to the prior approval of MediaLinx;

e)   host, manage, update and maintain all aspects of the mutually approved Co-      Branded Site including technology, content, production, design, operations,      and customer relations save and except forums. Without limiting the      generality of the foregoing, HCI shall use all reasonable commercial      efforts to: 1) ensure that the hosting services provided in connection with      the Co-Branded Site are provided at the same standard as the hosting of the      Sympatico web site, and 2) ensure that the Co-Branded Site is available 7      days per week and 24 hours per day;

f)   ensure that the level of Canadian content contained on the Co-Branded Site      is maintained at such levels as is found on the HealthyWay section of the      Sympatico web site on the Launch Date, and ensure that the level of      Canadian content is maintained in accordance with the attached Schedule      3;

g)   design the Co-Branded Site in such a manner so as to make prominent      Canadian content, Canadian context and Canadian activity, such as described      in Schedule 3;

h)   make all reasonable efforts to suppress or remove all content from the HCI      Site which is to be integrated into the Co-Branded Site that is irrelevant      and inappropriate for the Canadian market and ensure that all content      contained in the Co-Branded Site continues to be relevant for the Canadian      market in accordance with Schedule 3;

i)   provide MediaLinx with daily usage statistics for the Co-Branded Site in      accordance with the following format attached hereto as Schedule 4;

                                                                               3

j)   have the option to provide and manage some discussion forum hosts referred      to in paragraph 2(a) of this Agreement;

k)   ensure that it only utilizes communications related services and tools on      the Co-Branded Site which have been provided by MediaLinx's Canadian      telecommunication partners, including but not limited to webmail,      directories, address book, and ip telephony;

l)   grant to MLX, to the extent that MLX requires access to HCI logos and      trademarks (collectively HCI Marks) the use of certain HCI Marks as      necessary for the purposes of fulfilling its obligations under this      Agreement. MLX assures that the HCI Marks are used in accordance with HCI's      logo usage guidelines as provided by HCI from time to time. Without      limiting the generality of the foregoing, MLX agrees:

     (i)     that HCI is the owner of the HCI Marks and the goodwill and              reputation associated therewith;

     (ii)    not to contest the validity of the HCI Marks or HCI's title              thereto;

     (iii)   that MLX acquires no right, title or interest in the HCI Marks, and              any and all goodwill associated with the HCI Marks enures              exclusively to the benefit of HCI;

     (iv)    to notify HCI promptly of any attempt by any third party to use the              HCI marks, or any variation or imitation thereof of which MLX              becomes aware;

     (v)     at HCI's expense, to fully co-operate with HCI and execute such              documents and at the request of HCI to do such acts and things as              may be reasonably necessary or desirable to restrain such use; and

m)   ensure that in the event that it enters into an electronic commerce

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





     agreement with a third party for the sale of goods on the Co-Branded Site      that all agreements with the third parties shall ensure that such third      party shall be wholly responsible for all products and transactions that      may occur on the Co-Branded Site, that all such transactions shall comply      with all applicable Canadian and US laws and regulations, including privacy      laws and including compliance with MediaLinx's standards and guidelines,      and ensure that such third party provides a full indemnity to MediaLinx and      HCI in respect of any and all transactions and products that may be hosted      on the Co-Branded Site.

4.  ADVERTISING

Subject to paragraph 6, MediaLinx shall be entitled to sell advertising and sponsorships on all pages of the Co-Branded Site to Canadian advertisers (for the purposes of this Agreement Canadian advertisers shall be advertisers with substantial places of business in Canada) and HCI shall be entitled to sell advertising and sponsorships on all pages of the Co-Branded Site to US advertisers (for the purposes of this Agreement, US advertisers shall be advertisers with substantial places of business in the United States). All sponsorship and advertising package deals for the Co-Branded Site will be mutually agreed upon by the parties and shall abide by MediaLinx's and HCI's standard advertising agreement and Canadian and U.S. advertising regulations and standards. Any excess inventory that has not been sold is available to be sold by either party. Neither party shall permit advertising on the Co-Branded Site from an entity which is a competitor to the other party. For the purposes of this Agreement, a competitor to MediaLinx shall be an Internet portal web site and/or an internet service provider. For the purposes of this Agreement, a competitor to HCI shall be a consumer health based web site. The parties shall define a plan in writing prior to the Launch setting out how the Parties shall work together to jointly sell advertising, serve the advertising and track the advertising inventory on the Co-Branded Site.

                                                                               4

5.  E-COMMERCE

Subject to paragraph 6, MediaLinx and HCI shall be entitled to negotiate e- commerce relationships which shall reside on the Co-Branded Site. In addition to the terms and conditions detailed in paragraphs 2(e) and 3(m), both parties acknowledge and agree that any e-Commerce offering must be able to offer pricing in Canadian dollars and provide shipping across Canada, unless otherwise mutually agreed to in writing. In addition, all products offered through the Co- Branded Site must abide by all Canadian laws and regulations. The cost of integrating any e-Commerce relationship will be borne by the entity that brought the relationship. Any and all marketing activities and design of an e-Commerce system shall be approved by both parties.

6.  FINANCIALS

(a)  HCI shall pay MLX a guaranteed fixed sum of [*] US per annum during the      Initial Term of this Agreement to be paid out as a monthly payment of [*]      US (the Monthly Payment). This Monthly Payment shall be due by the 10th      day of each month;

(b)  HCI shall be entitled to all net revenue generated from advertising and e-      commerce transactions generated by Canadian companies that may take place      on the Co-Branded Site up to and including [*] US in any given year.      Thereafter, any net revenues exceeding [*] US shall be shared fifty-fifty      between the parties (50% MediaLinx--50% HCI). HCI shall be entitled to all      proceeds generated from US companies on the Co-Branded Site. Net revenue      is defined as revenue less: 1) third party expenses directly related to the      acquisition of the revenue; for example, advertising broker commissions and      advertising management services, and 2) internally paid commissions for      selling the advertisement and/or sponsorship;

(c)  Both Parties shall keep true and accurate books and records of all revenue      generated as a result of the Co-Branded Site. Either Party shall have the      right from time to time to audit and make extracts of the books and records      of the other, insofar as said books or records pertain to the terms of this      Agreement. Any such audit shall take place upon not less than seven (7)      days advance written notice, during normal business hours of normal      business days and at reasonable intervals. Any such audit shall be at the

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





     requesting Party's expense, unless the audit determines that the other      party has underpaid by 10% or more. In the event that the calculation of      payments herein is determined by a computer-based system, then the books      and records shall include, without limitation, the machine-sensible data      (e.g. punch cards, magnetic tapes, discs; and

(d)  Both Parties shall provide the other with quarterly accounting reports as      necessary. The quarterly reporting periods end September 30th and      December 31st, 1999, March 31st, 2000, and June 30th, 2000.      Applicable remittances and accounting reports will follow under separate      cover within sixty (60) days of the end of each quarter.

[*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                                                               5

7.  CUSTOMER INFORMATION

Any and all customer data that is collected from the Co-Branded Site shall be collected and used in accordance with Canadian federal and provincial laws and U.S. Federal and State laws and both MediaLinx and HCI privacy guidelines and MediaLinx and HCI shall each own an undivided interest in such data. MediaLinx will not have access to the HCI Personal Health Records (being the longitudinal repository of personal health information about users of the Co-Branded Site) during or after the Term of this Agreement. During the Term of this Agreement and for a period of six (6) months thereafter, MediaLinx shall not use or publicly disclose the data collected from users of the Co-Branded Site if such use is for the purpose of providing health information, advertisements, or products that compete with those that reside on the Co-Branded Site. In other instances, MediaLinx shall be entitled to use or publicly disclose the data collected subject to privacy guidelines noted above.

In addition to the foregoing, HCI shall ensure that the Co-Branded Site is integrated into the Sympatico site-wide registry in order for users to have a single login access for all Sympatico.ca and Sympatico co-branded web sites.

8.  PAGE VIEWS

Both MediaLinx and HCI shall be entitled to count the page views on the Co- Branded Site. In the event that it becomes necessary to have only one party count the number of page views on the Co-Branded Site, due to third party reporting, regulatory and/or legal requirements, HCI shall be entitled to count one hundred percent (100%) of the content page views of the Co-Branded Site and MLX shall be entitled to count one hundred percent (100%) of the HealthyWay discussion forum page views and one hundred percent (100%) of the page views on the Sympatico Health home page.

9.  EXCLUSIVITY

During the Term of the Agreement, and subject to the following requirements respecting Canadian content levels as set out in paragraphs 3(f), (g) and (h), HCI shall be the exclusive health content partner in the health section of the Sympatico web site, provided however, that nothing contained herein shall prevent MediaLinx from entering into an agreement with other parties for: i) a health based web directory; or ii) other health related content whose content does not compete with the content contained on the Co-Branded Site; which in no event shall receive no more than one fifth (1/5th) of the promotion and which shall constitute no more than one fifth (1/5th) of the total health related content which resides on the home page of the Sympatico Health section. In the event that MediaLinx obtains a web guide from a third party, MediaLinx and HCI shall discuss how to present both web guides to the user, and make best effort to agree to the kind of experience that the user shall have when utilizing the new web guide. If, at any time during the Term of this Agreement, HCI fails to meet the content requirements set out in paragraphs 3(f), (g) and (h), HCI shall no longer be entitled to be the exclusive health content partner in the health section of the Sympatico web site. HCI shall not either directly or indirectly license or deliver content to or carry on or be engaged with any other Canadian portal web site, being a Web site which aggregates and markets a variety of content directed to multiple communities of interest and which offers products,

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





tools and services to a broad base of Canadian end users.

                                                                               6

10.  BRANDING & COMMUNICATIONS

During the first six (6) months from the Launch date, the primary branding for the Co-Branded Site shall remain HealthyWay. In addition to the foregoing and subject to mutual design approval, a Powered By HealthCentral or such other appropriate tag line shall appear on the Co-Branded Site and shall be approximately 80% of the font size of the HealthyWay title and will be close to the HealthyWay brand. Thereafter, the HealthyWay and Health Central trademarks shall be co-branded in a mutually agreed upon method. The URL for the Co-Branded Site shall remain healthyway.sympatico.ca. A separate redirect URL may be set up for the Co-Branded Site, e.g. healthcentral.sympatico.ca.

All electronic communications to the users of the Co-Branded Site shall be jointly developed, co-branded with each party's respective marks and shall be mutually agreed upon.

11.  TERM & TERMINATION

11.1  Term

The term of this Agreement shall be for a period of two (2) years (the Term). The effective date of the start of the Term will be from the Launch Date.

11.2  Termination

(a)  Either Party may terminate this Agreement upon 30 days prior written notice      to the other Party if 1) such other Party breaches any material term of      this Agreement, unless such breach is cured within 30 days; or 2) if any of      the terms of this Agreement that require mutual approval are not mutually      agreed to;

(b)  This Agreement may be terminated by a Party immediately, without notice:

     (i)     upon the institution by or against the other Party of insolvency,              receivership, or bankruptcy proceedings or any other proceedings              for the settlement of the other Party's debts, if such proceedings              are not dismissed within sixty (60) days;

     (ii)    upon the other Party making an assignment for the benefit of              creditors; or

     (iii)   upon the other Party's dissolution;

(c)  Either party may terminate this Agreement upon 30 days written notice if      either Party's corporate structure has undergone a material ownership      change such that its corporate interests are then in conflict with the      corporate interests of the other Party; and

(d)  Upon termination or expiration of this Agreement for any reason:

     (i)     the Parties shall immediately cease using the Marks of the other              Party;

     (ii)    the Parties shall immediately return to each other all property of              the other and cease using or distributing all advertising or              promotional materials, if any, containing references to the other              Party or the other Party's product;

     (iii)   the Parties shall remove all special links made pursuant to this              Agreement from their respective products of the other Party; and

     (iv)    each Party shall pay to the other Party all outstanding amounts              which have accrued and are properly owing, including without              limitation, any New Account customer commission payments or net              advertising revenue owed outstanding together with any appropriate              final reports.

                                                                               7

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





11.3  The exercise of a right of termination or other right or remedy in       connection with this Agreement shall be without prejudice to any other       right or remedy to which the terminating party may be entitled under this       Agreement or applicable law.

12.  REPRESENTATIONS & WARRANTIES

(a)  MLX's Representations and Warranties.

MLX represents and warrants that:

(i)     it has full right, power and authority to enter into and be bound by the         terms and conditions of this Agreement and to perform its obligations         under this Agreement, without the approval or consent of any other         party;

(ii)    it has sufficient right, title and interest in and to the rights granted         to HCI pursuant to this Agreement to enter and perform this Agreement         and to enable HCI to perform under this Agreement;

(iii)   it owns all intellectual property in and to the MLX Marks and the         Sympatico Content, including but not limited to any and all creative         advertisement content, or has obtained all necessary licenses,         clearances, assignments and waivers in respect of any and all         intellectual property used in the Sympatico Content, including without         limitation waivers of moral rights necessary to publish, license and         distribute world-wide;

(iv)    the use, reproduction, distribution or transmission of the Sympatico         Content will not violate any laws including criminal laws, commercial         laws, or any rights of any third parties including, but not limited to         such violations as infringement or misappropriation of copyright,         patent, trademark, trade defamation, invasion of privacy or rights of         celebrity, violation of any anti-discrimination law or regulation, or         any other right of any person or entity;

(v)     it has all necessary skills and materials necessary to provide its         contributions to the Co-Branded Site as contemplated by this Agreement.         MLX shall perform the services described herein in a timely fashion with         all due skill, competence and diligence and the quality of the Co-         Branded Site shall meet both HCI's and MLX's standards of high quality         and excellence;

(vi)    that the information contained in the MLX marks and the MLX content is         accurate, does not contain any material that is libelous, obscene,         misleading or otherwise harmful.

(b)  HCI's Representations and Warranties.

HCI represents and warrants that:

(i)     it has full right, power and authority to enter into and be bound by the         terms and conditions of this Agreement and to perform its obligations         under this Agreement, without the approval or consent of any other         party;

(ii)    it has sufficient right, title and interest in and to the rights granted         to MLX pursuant to this Agreement to enter and perform this Agreement         and to enable MLX to perform under this Agreement;

(iii)   it owns all intellectual property in and to the HCI Marks and all         content HCI contributes to the Co-Branded Site (the HCI Content)         including but not limited to any and all creative

                                                                               8

        advertisement content, or has obtained all necessary licenses,         clearances, assignments and waivers in respect of any and all         intellectual property used in the HCI Marks and the HCI Content,         including without limitation waivers of moral rights necessary to

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





        publish, license and distribute world-wide;

(iv)    the use, reproduction, distribution or transmission of the HCI Marks and         HCI Content will not violate any laws including criminal laws,         commercial laws, or any rights of any third parties including, but not         limited to such violations as infringement or misappropriation of         copyright, patent, trademark, trade defamation, invasion of privacy or         rights of celebrity, violation of any anti-discrimination law or         regulation, or any other right of any person or entity;

(v)     the Co-Branded Site will function, operate and perform in all material         respects in accordance with the requirements described or incorporated         in the Agreement;

(vi)    it has all necessary skills and materials necessary to provide its         contributions to the Co-Branded Site as contemplated by this Agreement.         HCI shall perform the services described herein in a timely fashion with         all due skill, competence and diligence and the quality of the Co-         Branded Site shall meet both HCI's and MLX's standards of high quality         and excellence;

(vii)   that no advertisement submitted to MLX hereunder shall make use of any         subliminal technique and holds MLX and its affiliated and related         companies harmless against any loss or damage arising from the storage         and/or use of any and all advertising. HCI warrants that any and all         advertising that it submits complies with advertising standards in         Canada, including those of MLX and that the use, reproduction,         distribution, or transmission of such advertising will not violate any         criminal laws, commercial laws or any rights of any third parties,         including, but not limited to, such violations as infringement or         misappropriation of copyright, patent, trademark, trade secret, music,         image, video/full motion video or other proprietary or property right,         false advertising, unfair competition, defamation, invasion of privacy         or rights of celebrity, property right, false advertising, unfair         competition, defamation, invasion of privacy or rights of celebrity,         violation of any anti-discrimination law or regulation, or any other         right of any person or entity;

(viii)  that the Co-Branded Site will function, operate and perform in all         material respects in accordance with the requirements described in the         Agreement; and

(vix)   that the information contained in the HCI Marks and the HCI Content is         accurate, does not contain any material that is libelous, obscene,         misleading or otherwise harmful.

13.  NO ADDITIONAL WARRANTIES

a)   Except as specifically provided herein or as agreed to in writing by the      Parties, the services provided under this Agreement are not guaranteed and      are provided as is and MLX gives no representations, warranties or      conditions of any kind, express or implied, including without limitation      warranties as to insertion, display or loading of any advertisement,      sponsorship or integrated branded search engine uninterrupted or error free      operation of the Sympatico Web Site, any advertisement, sponsorship,      integrated branded search engine or link, merchantability, quality or      fitness for a particular purpose and those arising by statute or otherwise,      or from a course of dealing or usage of trade; and

                                                                               9

b)   Except as specifically provided herein or as agreed to in writing by the      parties: 1) the services provided under this Agreement are not guaranteed      and are provided as is; and 2) HCI gives no representations, warranties      or conditions of any kind, express or implied, including without limitation      warranties as to: insertion, display or loading of any advertisement,      sponsorship or integrated branded search engine uninterrupted or error free      operation of the co-branded Web Site, any advertisement, sponsorship,      integrated branded search engine or link, merchantability, quality or      fitness for a particular purpose and those arising by statute or otherwise,      or from a course of dealing or usage of trade.

14.  INDEMNIFICATION

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





(a)  By MLX: MLX agrees to indemnify and hold harmless HCI and its employees,      representatives, agents and affiliates from any and all liability, loss,      claims, damages or causes of action (each a Claim), including reasonable      legal fees and expenses that may be incurred by, arising out of or relating      to any claim that the MLX Marks or Sympatico Content or any MLX developed      advertising infringes in any manner any copyright, patent, trademark, trade      secret or any other intellectual property right of any third party;

(b)  By HCI: HCI agrees to indemnify and hold harmless MLX and its employees,      representatives, agents and affiliates from any Claim including reasonable      legal fees and expenses that may be incurred by, arising out of or relating      to any third party claim that the HCI Marks or HCI Content or any HCI      developed advertising infringes in any manner any copyright, patent,      trademark, trade secret or any other intellectual property right of any      third party; and

(c)  Procedure: All indemnification obligations under Section 14, shall be      subject to the following requirements:

     (i)     the indemnified party shall provide the indemnifying party with              prompt written notice of any Claim;

     (ii)    the indemnified party shall permit the indemnifying party to assume              and control the defense of any action upon the indemnifying party's              written acknowledgment of the obligation to indemnify; and

     (iii)   the indemnified party shall not enter into any settlement or              compromise of any Claim without the indemnifying party's prior              written consent, which shall not be unreasonably withheld.

     In addition, the indemnified party may, at its own expense, participate in      its defense of any Claim. In the event that the indemnifying party assumes      the defense of any such claim, the indemnifying party shall have no      liability for legal fees and costs incurred by the indemnified party.

15.  LIMITATION OF LIABILITY

EXCEPT WITH RESPECT TO THE INDEMNITY OBLIGATIONS IN SECTION 14, THE CONFIDENTIALITY OBLIGATIONS UNDER SECTION 16, AND THE YEAR 2000 COMPLIANCE OBLIGATIONS UNDER SECTION 20, NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE,

                                                                              10

STRICT LIABILITY, TORT OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOSS OF REVENUE OR GOODWILL OR ANTICIPATED PROFITS OR LOST BUSINESS), EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

16.  CONFIDENTIALITY

Each Party shall keep confidential any information, data and reports obtained in connection with this Agreement, unless such information has been rightfully obtained from a third party or is generally available to the public, or as must be disclosed by law. Upon termination of this Agreement, each of the parties (the Receiving Party) shall return to the other party (the Disclosing Party) any records or copies thereof which it may have obtained from the Disclosing Party in connection with its review of the Disclosing Party's business, other than information otherwise rightfully obtained by Receiving Party, acting in good faith, from someone other than the Disclosing Party or generally available to the public. Each party shall hold the terms and provisions of this Agreement confidential and shall not disclose its terms to any person except to its management. Notwithstanding the foregoing, this Agreement and the LOI is subject to the terms and conditions of the Confidentiality and Non-Disclosure Agreement signed between the Parties dated May 3rd, 1999.

17.  NO PUBLIC NOTICE

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





No public announcement of the proposed transaction will be made by either Party unless the timing and content have been agreed upon in advance by both parties, except as may otherwise be required by law. It is understood though that MediaLinx may discuss this arrangement with its Sympatico Internet service providers and affiliates to the extent necessary to meet the proposed time lines.

18.  COSTS

Unless agreed to otherwise, each party will pay for its own costs and expenses in connection with this Agreement and the proposed activities contemplated herein, without limitation, legal fees, brokers, accountants and other professional advisors.

19.  INDEPENDENT CONTRACTORS

It is the intention of MLX and HCI that MLX and HCI are, and shall be deemed to be, independent contractors with respect to the subject matter of this Agreement, and nothing contained in this Agreement shall be deemed or construed in any manner whatsoever as creating any partnership, joint venture, employment, agency, fiduciary or other similar relationship between MLX and HCI.

                                                                              11

20.  YEAR 2000 COMPLIANCE

Both MLX and HCI represent and warrant that their contributions to the Co- Branded Site are designed to be used prior to, during, and after the calendar year 2000 AD and will operate during each such time period without error relating to date data, specifically including any error relating to, or the product of, date data which represents or references different centuries or more than a century. Without limiting the generality of the foregoing, the Co-Branded Site: (i) will not abnormally end or provide invalid or incorrect results as a result of date data, specifically including date data which represents or references different centuries or more than one century; (ii) has been designed to ensure year 2000 compatibility, including, but not limited to, date data century recognition, calculations which accommodate same century and multi- century formulas and date values, and date data interface values that reflect the century; and (iii) includes Year 2000 Capabilities. For the purposes of this Agreement, Year 2000 Capabilities means the Co-Branded Site (i) will manage, calculate, sequence, compare and manipulate data involving dates, including single century formulas and multi-century formulas, including leap years and will not cause an abnormally ending scenario within the application or generate incorrect values or invalid results involving such dates; (ii) provides that all date-related user interface functionalities and data fields include the indication of century; and (iii) provides that all date-related data interface functionalities include the indication of century.

While HCI asserts that its code and scripts will execute properly, as described above, and that HCI uses third party software that specifies Y2K compliance, we can not guarantee that all third party software will perform as specified by the manufacturer. Should a third party product fail to meet its Y2K compliance policy, we will work with the vendor to remedy the problem in a timely fashion. HCI will ensure that it complies with any third party recommendations that are necessary for Y2K compliance.

21.  GOVERNING LAW

This Agreement shall be governed by and interpreted and enforced in accordance with the laws of the Province of Ontario and the Parties agree to abide by the jurisdiction of the Courts of Ontario.

22.  ENTIRE AGREEMENT

This Agreement, together with any and all attached exhibits and/or schedules, represents the entire agreement between MLX and HCI with respect to the subject matter herein and shall supercede all prior agreements, communications and understanding of the Parties, oral and/or written.

23.  LEGAL FEES

The prevailing Party in any legal action brought by one Party against the other and arising out of this Agreement shall be entitled, in addition to any other

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





rights and remedies it may have, to reimbursement for its expenses, including court and arbitration costs, as well as reasonable legal fees.

                                                                              12

24.  SUCCESSORS AND ASSIGNS

Except as provided in this Section, neither Party may assign its rights or obligations under this Agreement without the prior written consent of the other Party, which shall not be unreasonably withheld. Notwithstanding the foregoing, either party shall be permitted to assign this Agreement and any of its rights and obligations hereunder to an affiliate or related company or to a purchaser of all or substantially all of its Internet business, without obtaining the prior written consent of the other party.

25.  FORCE MAJEURE

Neither Party shall be liable for failure to perform or delay in performing any obligation under this Agreement if such failure or delay is due to fire, flood, earthquake, strike, war (declared or undeclared), embargo, blockade, legal prohibition, governmental action, riot, insurrection, damage, destruction or any other similar cause beyond the control of such Party.

26.  NOTICES

All notices, requests, consents and other communications which are required or permitted hereunder shall be in writing and shall be deemed given (a) when delivered in person at the time of such delivery or by telecopy with confirmed receipt of transmission at the date and time indicated on such receipt or (b) when received if given by an internationally recognized express courier service to the address specified below. Notice of change of address shall be given in the same manner as other communications.

If to HCI:                    If to MediaLinx: - ----------                    ----------------

HealthCentral.com Inc.        MediaLinx Interactive, L.P. 2600 Tenth Street             20 Richmond Street East, Suite 600 Berkeley, CA                  Toronto, Ontario, M5C 3B5 94710                         Attn: Director of Content                               Fax: (416) 350-1516                               with a copy to Legal Department:                               Fax No.: (416) 350-5212

27.  COUNTERPARTS

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument.

28.  HEADINGS

The section and article headings contained in this Agreement are included for convenience only, and shall not limit or otherwise affect the terms of this Agreement.

                                                                              13

                                  Schedule 1

MLX will run [*] advertising banners, promoting the Co-Branded Site each month, which shall run throughout the Sympatico.ca Site.

MLX will promote the Co-Branded Site on the Sympatico.ca homepage in a frequent and timely fashion.

MLX will promote the Sympatico Health Site through Sympatico.ca house advertising, from time to time.

MLX will provide contextual integration of Health content into other areas of

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





Sympatico.ca, as appropriate.

MLX will provide a persistent link, in fold, from the Sympatico Health Site home page to the Co-Branded Site.

MLX will provide a link to the Sympatico Health Site home page from the Sympatico.ca home page.

[*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.                                                                               14

                                  Schedule 2

MLX will use all commercially reasonable efforts to maintain the user traffic at a monthly minimum of:

 .  [*] page views three (3) months after the launch of the Co-Branded Site;

 .  [*] page views six (6) months after the launch of the Co-Branded Site; and

 .  [*] page views twelve (12) months after the launch of the Co-Branded Site.

[*]  = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                                                              15

                                  Schedule 3

HCI shall ensure that Canadian content and context is promoted and maintained within the Co-Branded Site in accordance with the following:

Ensure that Canadian spelling is used throughout the site where possible. Ensure that non-relevant or inappropriate information is either removed or put into context for a Canadian user. Ensure that Canadian health information sourced from Canadian content providers is added to the site, where possible.

Issues related to access to services: Canadian public health care system There is little notion of managed care in Canada Inclusion of Canadian self help resources

Health related law & policy: Federal and provincial government funding of healthcare and the existence of a social safety net in Canada Allowed distribution of drugs Different roles related to pharmaceutical advertising

Societal context of Canada: Canada's multicultural make up (e.g. Less Hispanics, more Asians) Likelihood of different health risk factors for Canadians Different behaviour of the Canadian population (e.g. travelling south for the winter, snowbirds) Different health events e.g. Heart month

Technicalities: Differences in drug names Canadian currency Metric system for measurement

The Canadian voice: Important to highlight Canadian health experts e.g. Canadian health professionals, researchers, companies local events e.g. hospital closures, labour issues

                                                                              16

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999





                                  Schedule 4

HCI will provide MLX with usage statistics in the following 2 formats:

1) access to real time online statistics through a web browser including a number of preprogrammed usage reports, and

2) a format mutually agreed to by HCI and MLX

                                                                              17

Source: HEALTHCENTRAL COM, S-1/A, 11/8/1999
[EX A]: Highlight the parts (if any) of this contract related to Covenant Not To Sue that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?

[EX Q]: Exhibit 10.3 Execution Version GWG HOLDINGS, INC., AND THE TRUST ADVISORS TO THE SELLER TRUSTS LISTED ON SCHEDULE A HERETO ORDERLY MARKETING AGREEMENT December 27, 2018





ORDERLY MARKETING AGREEMENT THIS ORDERLY MARKETING AGREEMENT (the OMA) is entered into on December 27, 2018 (the Effective Date) by and among GWG Holdings, Inc., a Delaware corporation (GWG), and the Trust Advisors to the Seller Trusts listed on Schedule A hereto (the Trust Advisors), and any other person or entity that becomes a party to this Agreement by executing and delivering a joinder hereto in the form attached as Exhibit A. Each of GWG and the Trust Advisors may be referred to herein as a Party and collectively as the Parties. WHEREAS, on January 18, 2018, GWG, the Trust Advisors and certain other entities entered into that certain Amended and Restated Master Exchange Agreement, with effect from January 12, 2018, as amended from time to time (the Master Agreement); and WHEREAS, the Trust Advisors are at all times acting hereunder as the representatives of and for the benefit of each Seller Trust named in the Master Agreement; WHEREAS, pursuant to Section 8.6 of the Master Agreement, GWG and the Trust Advisors agree to negotiate in good faith the terms of an agreement with one or more nationally recognized bulge bracket investment banks for the orderly marketing and resale of certain shares (the Shares) of common stock, par value $0.001 per share (the Stock) of GWG issued in reliance upon available exemptions from the Securities Act of 1933, as amended (the Act), under the terms of the Master Agreement to such Seller Trusts for the purpose of facilitating the establishment of a broader shareholder base and creating on-going liquidity in Stock; WHEREAS, contemporaneous with the execution of this OMA, the Trust Advisors and certain other entities are entering into a registration rights agreement (the Registration Rights Agreement) pursuant to which GWG is agreeing to file a registration statement on Form S-1 or other appropriate form (the Registration Statement) with the Securities and Exchange Commission (SEC) for the public offering of the Shares; WHEREAS, the entry into this OMA is a condition to the obligation of each of GWG and the Seller Trusts to consummate the various transactions contemplated by the Master Agreement; NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: Section 1. Orderly Marketing. 1.1 The shares of Stock held by each Seller Trust and subject to this OMA shall be as set out on Schedule A hereto, which Schedule may be amended from time to time in writing by the Parties in accordance with Section 4.1 below. 1.2 It is the goal of the Seller Trusts to have all of the Shares sold, on a pro-rata basis, in three or more tranches (each a Tranche) commencing not earlier than six (6) months after the Effective Date with the resale of all of the shares of Stock completed as soon as practicable after the Effective Date.

- 2 -





1.3 [Reserved]. 1.4 The Seller Trusts and GWG intend to retain one or more nationally recognized bulge bracket investment banks (the Bank) for the orderly marketing and resale of Shares pursuant to a separate engagement letter (the Engagement Letter) to advise them in connection with the sale of the Tranches (together, the Offerings). Such Engagement Letter shall include customary representations, warranties, covenants and indemnification provisions. The services to be performed by the Bank shall be set forth in such Engagement Letter and are expected to include, among others: (a) assisting in the drafting and preparation of one or more prospectus supplements describing GWG, the Shares and the terms of the Offerings; (b) advising the Seller Trusts on a marketing and distribution strategy for each Tranche of Shares, including whether a particular Tranche should be sold through a block trade, overnight bookbuild, or similar transaction; (c) assisting GWG in preparing marketing materials and conducting one or more roadshows and meetings with potential purchasers of the Shares; (d) advising the Seller Trusts as to the timing, structure and pricing of the Offerings; (e) providing other advisory services as are customary for similar transactions. The Engagement Letter shall include a requirement that, prior to any distribution of Stock by the Bank as contemplated by this Agreement, the Bank shall consult with each of GWG and the Trust Advisors as to the strategy for the marketing, sale and distribution of the respective Tranche. 1.5 After the Parties have agreed on the strategy for the marketing, sale and distribution of a Tranche, the Seller Trusts shall offer the Bank the right to serve as the lead left joint-book-running manager in connection with a best efforts distribution. GWG shall be entitled to appoint, in its discretion, an additional bank as joint book-running manager to participate in the distribution. The Seller Trusts further agree that in the event the Bank accepts such role it will be paid customary fees for the performance of its services in connection with such transactions and that such engagement will involve the execution of a standard form agreement with respect to the distribution of each Tranche, which may be in the form of a placement agency agreement, underwriting agreement or other appropriate agreement (each, a Distribution Agreement); provided, however, that nothing contained in this OMA or Engagement Letter shall require the Bank to underwrite or purchase all or any portion of a Tranche of Stock for its own account. Notwithstanding the foregoing, it is understood and agreed that the Bank or its affiliates may, solely at its discretion and without any obligation to do so, purchase Stock in any Tranche as principal.

- 3 -





1.6 Each such Distribution Agreement shall set out the customary terms and conditions for the sale and distribution of the respective Tranche, including customary representations, warranties, covenants and indemnification provisions. For the avoidance of doubt, each Distribution Agreement shall include provisions to the following effect: (i) GWG shall have no responsibility for the payment of fees or commissions payable to the Bank, which fees and commissions shall be the responsibility of certain affiliates of the Seller Trusts as set forth in the applicable Distribution Agreement; and (ii) each of GWG and the Seller Trusts shall agree to provide a customary indemnity in favor of the Bank and its affiliates. 1.7 If, in connection with the marketing, sale and distribution of a Tranche, the Bank determines that the number of Shares of Stock proposed to be included in the Tranche exceeds the number that can reasonably be sold, then the number of Shares of Stock shall be reduced accordingly on a pro-rata basis with respect to each of the Seller Trusts. 1.8 Prior to the offering of each Tranche, GWG shall provide the placement agents or underwriters in such Offering a list of the top 100 institutional holders of the Common Stock. In connection with any Offering, the Seller Trusts shall instruct the placement agents or underwriters to use their reasonable best efforts to (i) effect as wide a distribution of the Shares as is reasonably practicable without adversely affecting the pricing thereof and (ii) not sell any Shares to any person or Group (as such terms is used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) who, upon completion of the Offering, would have Beneficial Ownership (as defined in Rule 13d-3 under the Exchange Act) of shares of Common Stock representing in the aggregate 5.0% or more the total number of outstanding shares of Common Stock (or in the case of a person of the type described in Rule 13d-1(b)(1)(i) under the Exchange Act, 10% or more of the Total Voting Power). Section 2. Compensation. The Engagement Letter shall provide that the Bank shall not be entitled to any compensation for its advice hereunder or reimbursement of its expenses in connection with this OMA and shall only be entitled to compensation in connection with an Offering as provided in the Engagement Letter and related Distribution Agreement with respect to such Offering. Section 3. [Reserved] Section 4. General Provisions. 4.1 Term; Termination; Withdrawal of Bank. (a) This OMA shall expire upon the earlier of (i) the first anniversary of the Effective Date and (ii) the date that all Shares of Stock of the Seller Trusts as set forth on Schedule A hereto have been sold (the Term). Notwithstanding the foregoing, this OMA may be terminated with or without cause at any time after the Effective Date and without liability or continuing obligation by any of the Parties hereto (i) by mutual written agreement of all of the Parties; and (ii) in writing by the Trust Advisors in their sole discretion.

- 4 -





(b) The Engagement Letter shall provide that the Bank may terminate its engagement at any time upon not less than 45 days' prior written notice to the other Parties. In the event the Bank provides such notice at any time prior to the sale of greater than 50% of the Shares and within 12 months of the Effective Date, then GWG and the Trust Advisors may elect (A) to terminate this OMA or (B) to continue this OMA and to seek to appoint a substitute investment bank, in which case GWG, after consultation with the Trust Advisors, shall be entitled to appoint a substitute investment bank to serve as the lead joint-book-running manager for the sale of the Shares. In the event the Bank terminates the Engagement Letter at any time following the sale of greater than 50% of the Shares and within 12 months of the Effective Date, the termination thereof shall constitute a concurrent Termination of this OMA. 4.2 Amendments and Waivers. This OMA may be amended or modified in whole or in part, only by duly authorized agreement in writing executed by each of the Parties. 4.3 Notices. All notices and other communications among the Parties shall be in writing and shall be deemed to have been duly given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service or (iv) when received by facsimile or email (provided that a copy is subsequently delivered by one of the other methods permitted in (i) through (iii) of this Section 4.3), addressed as follows: If to GWG: 220 S. Sixth Street, Suite 1200 Minneapolis, MN 55402 Attention: Jon R. Sabes, CEO Email: jsabes@gwglife.com If to the Trust Advisors on behalf of the Seller Trusts: Jeffrey S. Hinkle Murray T. Holland As Trust Advisors to Each of the Seller Trusts set forth on Schedule A hereto c/o The Beneficient Company Group, L.P. 325 N. St. Paul Street, Suite 4850 Dallas, Texas 75201 Email: jhinkle@beneficient.com; mholland@mhtpartners.com

- 5 -





4.4 Assignments and Transfers by Seller Trusts. The provisions of this OMA shall be binding upon and inure to the benefit of the Seller Trusts and their respective successors and assigns. A Seller Trust may transfer or assign, in whole or from time to time in part, to one or more liquidating trusts its rights hereunder in connection with the transfer or resale of Stock held by such Seller Trust, provided that such Seller Trust complies with all laws applicable thereto and provides written notice of assignment to GWG promptly after such assignment is effected, and provided further that such liquidating trust and each beneficiary thereof executes a joinder to this OMA effective as of the date of such assignment or transfer. 4.5 Counterparts. This OMA may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 4.6 Severability. Any provision of this OMA that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the Parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable in any respect. 4.7 Further Assurances. The Parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 4.8 Entire Agreement. This OMA is intended by the Parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the Parties hereto in respect of the subject matter contained herein. This OMA supersedes all prior agreements and understandings between the Parties with respect to such subject matter. 4.9 Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This OMA, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this OMA or the negotiation, execution or performance of this OMA (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this OMA), will be construed in accordance with and governed by the law of the State of New York without regard to principles of conflicts of laws that would result in the application of the law of any other jurisdiction. Any action against any Party relating to the foregoing shall be brought in any federal or state court of competent jurisdiction located within the State of New York, and the Parties hereto hereby irrevocably submit to the non-exclusive jurisdiction of any federal or state court located within the State of New York over any such action. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

- 6 -





EACH PARTY TO THIS AGREEMENT HEREBY WAIVES, AND AGREES TO CAUSE ITS AFFILIATES TO WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS AGREEMENT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE. EACH PARTY TO THIS AGREEMENT HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. 4.10 Certain Representations of the Parties. Each of the Parties hereto represents, several and not jointly, that it has taken all action required of it to duly authorize this OMA and that no further action or approval is required on its behalf and, when executed and delivered, this OMA constitutes a valid and binding obligation of such Party, enforceable in accordance with its terms. 4.11 Further Assurances. Each Party agrees to take such further action that may be reasonably required of it, and to execute such documents or instruments, in order to effectuate the transactions contemplated by this OMA. 4.12 Seller Trusts and Trust Advisors. It is expressly understood and agreed that (a) this document is executed and delivered by Delaware Trust Company, not individually or personally, but solely as Trustee, pursuant to direction from the Trust Advisors and in the exercise of the powers and authority conferred and vested in Delaware Trust Company as Trustee pursuant to the Trust Agreements of the Seller Trusts (the Trust Agreements) and the Trustee is governed by and subject to the Trust Agreements and entitled to the protections, rights and benefits contained therein, (b) each of the representations, undertakings and agreements herein made on the part of the Seller Trusts and Trust Advisors is made and intended not as personal representations, undertakings and agreements by Delaware Trust Company but is made and intended for the purpose for binding only the Seller Trusts and respective trust estates (the Seller Trust Assets), (c) nothing herein contained shall be construed as creating any liability on Delaware Trust Company, individually or personally, to perform any covenant either expressed or implied contained herein, all such liability, if any, being expressly waived by the parties hereto and by any person claiming by, through or under the parties hereto, (d) under no circumstances shall Delaware Trust Company be personally liable for the payment of any indebtedness or expenses of the Seller Trusts or Trust Advisors or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Seller Trusts or Trust Advisors under this Agreement or any other related documents, and (e) under no circumstances shall the Trust Advisors be personally liable for the payment of any indebtedness or expenses or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken under this Agreement, all such recourse being strictly to the Seller Trust Assets. [Remainder of Page Intentionally Left Blank; Next Page is Signature Page]

- 7 -





IN WITNESS WHEREOF, the Parties hereto have executed this OMA as of the date first set forth above. GWG HOLDINGS, INC. By: /s/ Jon R. Sabes Name: Jon R. Sabes, CEO THE LT-1 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-2 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 8 -





THE LT-3 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-4 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-5 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-6 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 9 -





THE LT-7 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-8 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-9 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-12 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 10 -





THE LT-13 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-14 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-15 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-16 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 11 -





THE LT-17 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-18 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-19 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-20 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 12 -





THE LT-21 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-22 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-23 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-24 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President

- 13 -





THE LT-25 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President THE LT-26 EXCHANGE TRUST, By: DELAWARE TRUST COMPANY, not in its individual capacity but solely as Trustee By: /s/ Alan R. Halpern Name: Alan R. Halpern Title: Vice President MURRAY T. HOLLAND, as Trust Advisor /s/ MURRAY T. HOLLAND JEFFREY S. HINKLE, as Trust Advisor /s/ JEFFREY S. HINKLE

- 14 -





SCHEDULE A List of Seller Trusts and Shares of Stock

Name of Record Holder Number of  Shares The LT-1 Exchange Trust 1,397,705 The LT-2 Exchange Trust 1,396,863 The LT-3 Exchange Trust 2,563,777 The LT-4 Exchange Trust 2,537,152 The LT-5 Exchange Trust 2,516,313 The LT-6 Exchange Trust 2,535,832 The LT-7 Exchange Trust 2,526,515 The LT-8 Exchange Trust 2,536,840 The LT-9 Exchange Trust 404,110 The LT-12 Exchange Trust 80,402 The LT-13 Exchange Trust - The LT-14 Exchange Trust 204,064 The LT-15 Exchange Trust 63,834 The LT-16 Exchange Trust 920,349 The LT-17 Exchange Trust 39,347 The LT-18 Exchange Trust 81,860 The LT-19 Exchange Trust 224,917 The LT-20 Exchange Trust 4,601 The LT-21 Exchange Trust 555,751 The LT-22 Exchange Trust 555,750 The LT-23 Exchange Trust 1,466,884 The LT-24 Exchange Trust 1,466,883 The LT-25 Exchange Trust 1,466,884 The LT-26 Exchange Trust 1,466,883

- 15 -





EXHIBIT A FORM OF JOINDER The undersigned is executing and delivering this Joinder Agreement pursuant to that certain Orderly Marketing Agreement, dated as of December [___], 2018 (as amended, restated, supplemented or otherwise modified in accordance with the terms thereof, the OMA), by and among GWG Holdings, Inc., the Trust Advisors to the Seller Trusts listed on Schedule A thereto, and the Priority Holders listed on Schedule B thereto, and any other person or entity that becomes a party to the OMA in accordance with the terms thereof. Capitalized terms used but not defined in this Joinder Agreement shall have the respective meanings ascribed to such terms in the OMA. By executing and delivering this Joinder Agreement to the OMA, the undersigned hereby agrees, effective commencing on the date hereof, to become a party to, and to be bound by and comply with the provisions of, the OMA applicable to it as a holder of Shares, in the same manner as if the undersigned were an original signatory to the OMA. The undersigned acknowledges and agrees that Section 4.1 through Section 4.11 of the OMA are incorporated herein by reference, mutatis mutandis. [Remainder of page intentionally left blank; signature appears on next page]

- 16 -





Accordingly, the undersigned have executed and delivered this Joinder Agreement as of the ____ day of ________________, _____. Name: [HOLDER/TRANSFEREE] By: Name: Title: Notice Information Address: Telephone: Facsimile: Email: AGREED AND ACCEPTED as of the day of , . GWG HOLDINGS, INC. By: Name: Title: [TRANSFEROR (if applicable)] By: Name: Title:

- 17 -
[EX A]: Highlight the parts (if any) of this contract related to Termination For Convenience that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?

[EX Q]: [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 10.2 FIRST AMENDMENT TO SUPPLY AND MANUFACTURING AGREEMENT This First Amendment (Amendment) to the Supply and Manufacturing Agreement dated April 1, 2017 between Cerus Corporation (Cerus) and Porex Corporation (Porex) (the Agreement) is made this 22 day of June 2018. RECITALS A. Cerus and Porex have agreed to make certain changes to the raw material and process to develop Components and such changes have resulted in a change to the cost and expense structure originally contemplated by the Agreement; B. Pursuant to Section 3 of the Agreement, Cerus and Porex have mutually agreed to temporarily modify the pricing for Platelet Wafers set forth on Exhibit D and to proactively set a cost structure for non-production related work. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, the parties hereby agree to amend the Agreement as follows: 1. New Exhibits AA-1, AA-2, AA-3 and AA-4, as set forth in Schedule 1 to this Amendment, shall be attached to the Agreement (inserted between Exhibit A-5 and Exhibit B-1) and incorporated therein by reference. The parties acknowledge and agree that Exhibits AA-1, AA-2, AA-3 and AA-4 set forth the revised specifications for Platelet Wafers manufactured by Porex for Cerus (collectively, the Revised Wafer Specifications). Unless otherwise agreed in writing, Porex shall continue to manufacture and produce Platelet Wafers using the existing specifications for Platelet Wafers until Cerus gives written notice to Porex that Platelet Wafers shall be thereafter manufactured in accordance with the Revised Wafer Specifications. References in the Agreement to Specifications shall be interpreted to include the Revised Wafer Specifications, as applicable. 2. A new Exhibit D-1, as set forth in Schedule 2 to this Amendment, shall be attached to the Agreement and incorporated therein by reference. As of April 1, 2018 and continuing until Cerus determines, in its sole discretion, that the Protocol EPP-029-886 under which Porex is currently operating can be discontinued, the price for Platelet Wafers shall be the prices set forth in Exhibit D-1. Upon Cerus' determination that the Protocol EPP-029- 886 can be discontinued, Cerus shall provide written notice thereof to Porex, along with a new purchase order for Platelet Wafers (the New Pricing PO). On and after the date of such notice, the Pricing table for Platelet Wafers in Exhibit D, as of the date immediately preceding the date of this Amendment, shall be reinstated and apply to Platelet Wafers that are produced pursuant to the New Pricing PO and were also produced after the date of the written notice. References in Section 1.5.1 of the Agreement to Exhibit D shall be amended to include Exhibit D-1, as applicable. 3. The penultimate sentence in Section 1.3 shall be deleted in its entirety and replaced with the following: In no event shall any Purchase Order: require delivery of more than [*] units of [*] and [*] units of [*] in any [*] (the Porex Capacity Limitations). 4. A new Section 1.5.3 shall be added to the Agreement as follows:





1.5.3 Porex will invoice Cerus monthly for Services performed by Porex during the prior month. Unless otherwise expressly provided in the applicable Statement of Work payment to Porex of undisputed fees shall be due [*] days following Cerus' receipt of the invoice submitted by Porex. Payment information, including Tax Identification Number will be included on each invoice.

Cerus shall have the right to accept or reject the Services, or any portion thereof, in writing within [*] days from Porex's completion of the Services. Such acceptance or rejection shall be consistent with the criteria set forth in the Statement of Work, if any. If Cerus does not reject in writing within [*] days, the Services shall be considered accepted by Cerus. Within [*] days of any notice of rejection, Porex shall present a corrective plan of action to Cerus. Upon approval by Cerus of the corrective plan, Porex, at no additional expense to Cerus, shall then make the corrections and, where applicable, Porex shall resubmit the corrected Services to Cerus. For disputed invoices or the disputed portion of an invoice, Cerus shall use reasonable efforts to provide to Porex, in writing, within [*] days, a description of the disputed amounts. Cerus and Porex shall negotiate in a timely, good faith manner to resolve billing queries. Cerus will not have responsibility to pay for identified errors, incomplete or inaccurate items (collectively the invoice errors) which result in increases to previously invoiced amounts if the aforementioned invoice errors are communicated to Cerus later than [*] days from the original invoice date.

5. A new Section 3a shall be added to the Agreement as follows: 3a Non-Production Related Work. From time to time, Cerus may submit to Porex written work orders substantially in the form of Schedule 3 that specify development activities, engineering analysis, part, material and/or fixture design and development, or other services or activities that Cerus requests Porex to perform that are not activities or services that are necessary for the then-current manufacture and production of Components for Cerus under the Agreement (collectively, as defined in each work order, the Services). Each work order shall set forth the terms and conditions (including specifications (if applicable), delivery and performance schedules, and fees) pursuant to which Porex will perform the Services. Upon acceptance of a work order by Porex (in writing), such work order shall become a Statement of Work. If Porex begins to perform services under a work order that has not been formally agreed in writing, then Porex shall bear the costs of any expenses incurred prior to formal written agreement of the Statement of Work. Cerus hereby consents to Porex's use of the Cerus Dedicated Space and Equipment, as specified in a Statement of Work, solely as necessary to perform the Services under that Statement of Work. Such consent shall automatically terminate upon the completion of the applicable Statement of Work and is limited by the terms of the Agreement. In the event of any conflict between the Agreement and a Statement of Work, the Agreement shall control unless the Statement of Work expressly refers to the Parties' intent to alter the terms of the Agreement with respect to that Statement of Work and shall not be construed as an amendment to the terms of the Agreement. 6. A new section titled Pricing for Non-Production Related Work Orders from Cerus is added to Exhibit D as set forth in Schedule 2 attached. Such pricing, upon mutual agreement of the Parties, shall apply to any Statement of Work mutually agreed by the Parties pursuant to Section 3a. 7. No other changes are made to the Agreement, including without limitation, the original Exhibit D, and the Agreement, the Plasma Disk pricing and related information as set forth in Exhibit D remain the same. Except as amended herein, the Agreement shall remain in full force and effect. Capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Agreement. IN WITNESS WHEREOF, the undersigned have caused this First Amendment to be signed, all as of the date first written above.

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Porex: Porex Corporation By: /s/ Tore Wistedt Name: Tore Wistedt Title: SR VP Global Strategy Marketing

Cerus: Cerus Corporation By: /s/ Kevin D. Green Name: Kevin D. Green Title: VP Finance and CFO

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Schedule 1 Exhibit AA-1 SPC 00562 {7 pages omitted}

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Exhibit AA-2 SPC 00628 {3 pages omitted}

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Exhibit AA-3 SPC 00628A {3 pages omitted}

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Exhibit AA-4 SPC 00628B {2 pages omitted}

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





Schedule 2 Exhibit D-1 Pricing [*] Pricing [*]

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





SCHEDULE 3

FORM STATEMENT OF WORK

This Statement of Work is incorporated into the Amended and Restated Supply and Manufacturing Agreement dated April 1, 2017 by and between Cerus Corporation and Porex Corporation, as amended by First Amendment to Supply and Manufacturing Agreement, effective April 1, 2018 (for the purposes of this Statement of Work, the Agreement). This Statement of Work describes Services to be performed and provided by Porex pursuant to the Agreement. All capitalized terms used and not expressly defined in this Statement of Work will have the meanings given to them in the Agreement. Approach Deliverables Obligations of Cerus, if any Specifications Points of Contact For Cerus: Contact name Address Phone Email For Porex: Contact name Address Phone Email Budget Payment Schedule In full consideration for Porex's timely and satisfactory performance of the Services, Porex will be compensated as follows: Term

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





The term of this Statement of Work will begin on ___________ and shall terminate on ____________.

Cerus Corporation

Signed: Name: Title: Dated:

Porex Corporation

Signed: Name: Title: Dated:

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
[EX A]:
Highlight the parts (if any) of this contract related to Effective Date that should be reviewed by a lawyer. Details: The date when the contract is effective